Resources
Connect With ATA
Thyroid News
Clinical Thyroidology – Highlighted Article
From Clinical Thyroidology: Is the Long-Term Prognosis of Differentiated Thyroid Cancer Affected When First Diagnosed During Pregnancy? -Few data are available in the literature on the detection of residual disease in women diagnosed with differentiated thyroid carcinoma (DTC) during or within 2 years after pregnancy
ATA 2014 Call for Abstract Submissions
The 2014 Abstract Site is now Open
Regular call:
Site Opens – Wednesday, April 9, 2014
Site Closes – Wednesday, June 18, 2014
Clinical Thyroidology for the Public – highlighted article
From Clinical Thyroidology for the Public: Thyroid hormone treatment of central hypothyroidism has a beneficial influence on cardiovascular risk factors - The hypothalamus (a region of the brain) and pituitary gland secrete hormones that regulate the function of thyroid gland, including thyroid hormone production
U.S. Prescribing Information for Thyrogen Revised to Include Use of Wider Range of Radioiodine in Patients
Revised label will facilitate use of Thyrogen to greater number of patients for postoperative thyroid remnant ablation, March 27, 2014
CAMBRIDGE, Mass. – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the Food and Drug Administration (FDA) approved revised prescribing information for the use of Thyrogen® (thyrotropin alfa for injection) to widen the dose range of radioiodine (RAI) when used for thyroid remnant ablation. Read More…
THYROGEN® Highlights of Prescribing Information (PDF File, 666KB)
